About Us
It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout.
It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout.
U.S. FDA scientists concluded that studies using adult human primary tissue more accurately predict real-world clinical outcomes than traditional preclinical models. By capturing how drugs affect the human heart in a physiologically relevant way, the research showed that human-based data provides earlier, more reliable insight into cardiac risk. The findings also underscore the strategic value of human tissue models in reducing translational gaps, improving decision-making confidence and helping teams advance safer programs into the clinic.
In this installment of the AnaBios Translational Research Webinar Series, Bruce Bean, Professor of Neurobiology at Harvard Medical School, examines the role of Nav1.8 voltage-gated sodium channels in human dorsal root ganglion neurons and their importance in acute pain signaling. Drawing on new preclinical data with suzetrigine (Journavx), a selective Nav1.8 inhibitor, Dr. Bean highlights how state- and temperature-dependent channel inhibition at physiological temperatures alters neuronal firing. The findings provide clear mechanistic insight into why Nav1.8 is a clinically relevant target for pain therapeutics and underscore the value of human-relevant models in advancing translational pain research.
AnaBios offers high-quality human tissue and cells recovered through our extensive network of hospitals and organ procurement organizations. We utilize proprietary methods, practices and streamlined logistics to maximize the preservation of physiological function. Our goal is to deliver industry-leading human tissues and cells for scientific research and drug discovery.
AnaBios creates the unprecedented opportunity for researchers to develop safer, more effective drugs while reducing time-to-market and clinical development costs. Accordingly, we have developed proprietary processes for functional ex vivo human platforms that redefine the concept of “First in Human” studies and bring true human biology to early pre-clinical discovery.
A newly published study, co-authored by AnaBios in collaboration with Cytokinetics and published on bioRxiv, highlights the power of human-relevant translational models to advance research in cardiac hypercontractility and heart failure with preserved ejection fraction (HFpEF). The work integrates mechanistic biochemistry with functional data from human cardiomyocytes, engineered heart tissues and a clinically relevant HFpEF animal model to demonstrate improvements in cardiac relaxation, structure, and fibrosis—key hallmarks of disease progression. This collaborative effort underscores how physiologically relevant human systems can generate deeper insight into cardiac dysfunction and support the development of next-generation cardiovascular therapies.
